Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorEuvrard, Sylvie-
dc.contributor.authorMorelon, Emmanuel-
dc.contributor.authorMorelon, Lionel Rostaing-
dc.contributor.authorGoffin, Eric-
dc.contributor.authorBrocard, Anabelle-
dc.contributor.authorTromme, Isabelle-
dc.contributor.authorBroeders, Nilufer-
dc.contributor.authorMarmol, Veronique del-
dc.contributor.authorChatelet, Valérie-
dc.contributor.authorDompmartin, Anne-
dc.contributor.authorKessler, Michèle-
dc.contributor.authorSerra, Andreas L.-
dc.contributor.authorHofbauer, Günther F.L.-
dc.contributor.authorPouteil-Noble, Claire-
dc.contributor.authorCampistol Plana, Josep M.-
dc.contributor.authorKanitakis, Jean-
dc.contributor.authorRoux, Adeline S.-
dc.contributor.authorDecullier, Evelyne-
dc.contributor.authorDantal, Jacques-
dc.contributor.authorCruzado, Josep Ma.-
dc.contributor.authorTUMORAPA Study Group-
dc.description.abstractBackground: transplant recipients in whom cutaneous squamous-cell carcinomas develop are at high risk for multiple subsequent skin cancers. Whether sirolimus is useful in the prevention of secondary skin cancer has not been assessed. Methods: in this multicenter trial, we randomly assigned transplant recipients who were taking calcineurin inhibitors and had at least one cutaneous squamous-cell carcinoma either to receive sirolimus as a substitute for calcineurin inhibitors (in 64 patients) or to maintain their initial treatment (in 56). The primary end point was survival free of squamous-cell carcinoma at 2 years. Secondary end points included the time until the onset of new squamous-cell carcinomas, occurrence of other skin tumors, graft function, and problems with sirolimus. Results: survival free of cutaneous squamous-cell carcinoma was significantly longer in the sirolimus group than in the calcineurin-inhibitor group. Overall, new squamous-cell carcinomas developed in 14 patients (22%) in the sirolimus group (6 after withdrawal of sirolimus) and in 22 (39%) in the calcineurin-inhibitor group (median time until onset, 15 vs. 7 months; P=0.02), with a relative risk in the sirolimus group of 0.56 (95% confidence interval, 0.32 to 0.98). There were 60 serious adverse events in the sirolimus group, as compared with 14 such events in the calcineurin-inhibitor group (average, 0.938 vs. 0.250). There were twice as many serious adverse events in patients who had been converted to sirolimus with rapid protocols as in those with progressive protocols. In the sirolimus group, 23% of patients discontinued the drug because of adverse events. Graft function remained stable in the two study groups. Conclusions: switching from calcineurin inhibitors to sirolimus had an antitumoral effect among kidney-transplant recipients with previous squamous-cell carcinoma. These observations may have implications concerning immunosuppressive treatment of patients with cutaneous squamous-cell carcinomas. (Funded by Hospices Civils de Lyon and others; TUMORAPA number, NCT00133887).-
dc.format.extent11 p.-
dc.publisherMassachusetts Medical Society-
dc.relation.isformatofReproducció del document publicat a:
dc.relation.ispartofNew England Journal of Medicine, 2012, vol. 367, num. 4, p. 329-339-
dc.rights(c) Massachusetts Medical Society, 2012-
dc.subject.classificationTrasplantament renal-
dc.subject.classificationCàncer de pell-
dc.subject.classificationÚs terapèutic-
dc.subject.otherImmunosupressive agents-
dc.subject.otherKidney transplantation-
dc.subject.otherSkin cancer-
dc.subject.otherTherapeutic use-
dc.titleSirolimus and secondary skin-cancer prevention in kidney transplantation-
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
642237.pdf538.13 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.